The belief for years has been that pancreatic tumors were an immune desert because it has too few mutations to flag and too dense a stromal wall to penetrate. This trial suggests the wall can be climbed, if you give the immune system the right map: a personalized neoantigen set, manufactured in weeks, and delivered as mRNA.
